1h Free Analyst Time
The addisons disease therapeutics market is forecasted to grow by USD 442.4 million during 2023-2028, accelerating at a CAGR of 6.59% during the forecast period. The report on the addisons disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by special drug designations, reformulation of drugs, and favourable reimbursement scenario.
The addisons disease therapeutics market is segmented as below:
By Therapy
- Oral drugs
- Parenteral drugs
By End-user
- Hospitals and clinics
- Diagnostic laboratories
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the addisons disease therapeutics market covers the following areas:
- Addisons disease therapeutics market sizing
- Addisons disease therapeutics market forecast
- Addisons disease therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global addisons disease therapeutics market: Abbott Laboratories, Actiza Pharmaceutical Pvt. Ltd., Akorn Operating Co LLC, Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Bio Techne Corp., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., BTL Biotechno Labs Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is expanding research into development of regenerative therapy."
According to the report, one of the major drivers for this market is the special drug designations.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Actiza Pharmaceutical Pvt. Ltd.
- Akorn Operating Co LLC
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Bayer AG
- Bio Techne Corp.
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- BTL Biotechno Labs Pvt. Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals Plc
- Lupin Ltd.
- Merck and Co. Inc.
- Neurocrine Biosciences Inc.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
